Stage A (Baseline Assessment) - Current practices will be assessed using one of the following identified performance measures. Please select one of the options below:

Stage A Option 1:	Stage A Option 2:
Screening Log - Baseline Form Review charts of at least 5 patients currently on anti-depressant therapy Complete the log Your staff may assist you with retrieving this data Fax the log to 847-440-8800	Baseline Assessment Survey Complete the survey based on your current practice Your responses will be captured within the platform Program findings will be provided to learners that provide email addresses

Stage B (Implementation) - Following completion of Stage A (Baseline Assessment), participating providers will receive tools/resources to address practice-based issues and performance change.

Stage B Option 1:	Stage B Option 2:
Screening Log - Implementation Form Review Implementation Period Resource Toolkit (IPRT) Complete the Screening log: Implementation on the next 5-10 patients Your staff may assist you with retrieving this data Fax the log to 847-440-8800	Review and implement tools/resources Review "Tools/Resources" Integrate tools/resources into your daily practice for minimum of 12 weeks Complete Utilization of Resources Survey

Stage C (Close-out) - Participating providers will be able to reevaluate the performance of their practices by comparing results from Stage C (Close-out) with Stage A (Baseline Assessment).

Stage C Option 1:	Stage C Option 2:
Post Activity Survey Close-out evaluation	Follow-Up Survey Close-out evaluation

Release date: April 2009
Expiration date: August 15, 2010

This educational initiative has been granted an exemption from the requirement for institutional review board (IRB) review by the Western Institutional Review Board (WIRB) under exemption criteria 45 CFR ~46.l01(b)(2).

However, please note that this exemption is not intended to supersede any requirements for IRB review in individual organizations and before participating, you should first ensure accordance with the regulations of your institution.

Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

Credit Designation
Performance Improvement Component
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 20.0 AMA PRA Category 1 Credits™. Participants should only claim credit commensurate with the extent of their participation in the activity.

AAFP
This activity has been reviewed and is acceptable for up to 20 Prescribed credit(s) by the American Academy of Family Physicians. AAFP accreditation begins April 15, 2009. Term of approval ends August 15, 2011.

Glenn J. Treisman, MD, PhD
Professor of Psychiatry and Behavioral Sciences, and of Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Joyce E. King, MD
Associate Director, Family Medicine Residency
Franklin Square Hospital
Baltimore, Maryland

Andrew A. Nierenberg, MD
Professor of Psychiatry, Harvard Medical School
Director NIMH Bipolar Trials Network
Co-Director, Bipolar Clinic and Research Program
Associate Director, Depression Clinical and Research Program
Massachusetts General Hospital
Boston, Massachusetts

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following.

Glenn J. Treisman, MD, PhD                 
Dr. Treisman has no relevant financial interests to disclose.

Joyce E. King, MD                 
Dr. King has no relevant financial interests to disclose.

Andrew A. Nierenberg, MD                       
Forest Pharmaceuticals, Inc., National Institute of Mental Health (NIMH), Pam Labs, Pfizer Pharmaceuticals, Inc. (grant/research support); Appliance Computing, Inc., Astra Zeneca PLC, Basilea Pharmaceutica, Ltd., Brain Cells, Inc., Bristol-Myers Squibb, Inc., PGX Health, Eli Lilly and Co., Jazz Pharmaceuticals, MGH Psychiatry Academy, Merck & Co., Inc., NIMH, Novartis Pharmaceuticals, Inc., Schering-Plough Corp., Shire Pharmaceuticals Group, Takeda Pharmaceutical, Co., Targacept(advisory board, consultant, honorarium)

No faculty member has indicated that their presentation will include information on off-label products.

The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients. Richard H. Kennison, DPM, MBA, CCMEP
President and General Manager

Dr. Kennison has no relevant financial relationships with commercial entities to disclose.

AlexAndria M Kung, MPH, PhD Candidate
Senior Medical Liaison

Ms. Kung has no relevant financial relationships with commercial entities to disclose.